Peter M.A. Calverley

440 total papers · 38.6k total citations
257 papers, 25.5k citations indexed

About

Peter M.A. Calverley is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Emergency Medical Services. According to data from OpenAlex, Peter M.A. Calverley has authored 257 papers receiving a total of 25.5k indexed citations (citations by other indexed papers that have themselves been cited), including 231 papers in Pulmonary and Respiratory Medicine, 145 papers in Physiology and 13 papers in Emergency Medical Services. Recurrent topics in Peter M.A. Calverley's work include Chronic Obstructive Pulmonary Disease (COPD) Research (215 papers), Asthma and respiratory diseases (129 papers) and Respiratory Support and Mechanisms (123 papers). Peter M.A. Calverley is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (215 papers), Asthma and respiratory diseases (129 papers) and Respiratory Support and Mechanisms (123 papers). Peter M.A. Calverley collaborates with scholars based in United Kingdom, United States and Netherlands. Peter M.A. Calverley's co-authors include Jørgen Vestbo, Klaus F. Rabe, Bartolomé R. Celli, Christine Jenkins, Stephen I. Rennard, Julie Yates, Antonio Anzueto, Emiel F.�M. Wouters, William MacNee and Ruth Tal‐Singer and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Peter M.A. Calverley

246 papers receiving 24.7k citations

Hit Papers

Global Strategy for the D... 2003 2026 2010 2018 2007 2010 2003 2010 2010 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
    2007 3.9k citations Klaus F. Rabe, Suzanne S. Hurd et al. American Journal of Respiratory and Critical Care Medicine profile →
  2. Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
    2010 2.1k citations John R. Hurst, Jørgen Vestbo et al. New England Journal of Medicine profile →
  3. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial
    2003 897 citations Peter M.A. Calverley, Romain Pauwels et al. The Lancet profile →
  4. Characterisation of COPD heterogeneity in the ECLIPSE cohort
    2010 815 citations Àlvar Agustí, Peter M.A. Calverley et al. Respiratory Research profile →
  5. Chronic Obstructive Pulmonary Disease Phenotypes
    2010 723 citations MeiLan K. Han, Àlvar Agustí et al. American Journal of Respiratory and Critical Care Medicine profile →
  6. Changes in Forced Expiratory Volume in 1 Second over Time in COPD
    2011 675 citations Jørgen Vestbo, Lisa Edwards et al. New England Journal of Medicine profile →
  7. Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype
    2012 618 citations Àlvar Agustí, Lisa Edwards et al. PLoS ONE profile →
  8. The Prevention of Chronic Obstructive Pulmonary Disease Exacerbations by Salmeterol/Fluticasone Propionate or Tiotropium Bromide
    2007 603 citations Jadwiga A. Wedzicha, Peter M.A. Calverley et al. American Journal of Respiratory and Critical Care Medicine profile →
  9. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
    2009 574 citations Peter M.A. Calverley, Klaus F. Rabe et al. The Lancet profile →
  10. Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease
    2003 561 citations Peter M.A. Calverley, Watchara Boonsawat et al. European Respiratory Journal profile →
  11. Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease
    2008 543 citations Bartolomé R. Celli, Julie A. Anderson et al. American Journal of Respiratory and Critical Care Medicine profile →
  12. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline
    2017 449 citations Jadwiga A. Wedzicha, Marc Miravitlles et al. European Respiratory Journal profile →
  13. Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD
    2014 403 citations H Magnussen, Bernd Disse et al. New England Journal of Medicine profile →
  14. Inflammatory Biomarkers Improve Clinical Prediction of Mortality in Chronic Obstructive Pulmonary Disease
    2012 312 citations Bartolomé R. Celli, Nicholas Locantore et al. American Journal of Respiratory and Critical Care Medicine profile →
  15. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial
    2016 307 citations Jørgen Vestbo, Julie A. Anderson et al. The Lancet profile →
  16. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials
    2018 298 citations Mona Bafadhel, Stefan Peterson et al. The Lancet Respiratory Medicine profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Peter M.A. Calverley 22.7k 13.1k 1.7k 1.7k 1.6k 257 25.5k
Christine Jenkins 16.9k 0.7× 10.6k 0.8× 1.7k 1.0× 1.1k 0.6× 1.5k 0.9× 247 21.0k
Marc Decramer 19.5k 0.9× 9.2k 0.7× 1.3k 0.8× 1.8k 1.1× 835 0.5× 394 24.3k
Jadwiga A. Wedzicha 21.6k 0.9× 9.6k 0.7× 3.4k 2.0× 1.3k 0.8× 2.4k 1.5× 253 24.7k
A. Sonia Buist 18.8k 0.8× 11.6k 0.9× 1.8k 1.0× 1.2k 0.7× 1.7k 1.1× 219 25.1k
Joan B. Soriano 15.5k 0.7× 9.6k 0.7× 1.8k 1.1× 975 0.6× 1.1k 0.7× 360 19.6k
Robert A. Stockley 15.9k 0.7× 6.3k 0.5× 2.0k 1.1× 1.1k 0.6× 1.5k 0.9× 329 21.9k
Barry J. Make 14.5k 0.6× 6.3k 0.5× 1.3k 0.8× 1.1k 0.7× 892 0.6× 272 17.3k
Don D. Sin 24.6k 1.1× 12.3k 0.9× 3.0k 1.8× 3.3k 1.9× 2.1k 1.3× 501 33.4k
Romain Pauwels 18.3k 0.8× 17.6k 1.4× 1.2k 0.7× 547 0.3× 1.7k 1.1× 146 26.3k
Roberto Rodríguez-Roisin 15.3k 0.7× 6.9k 0.5× 1.7k 1.0× 1.3k 0.7× 1.3k 0.8× 65 17.8k

Countries citing papers authored by Peter M.A. Calverley

Since Specialization
Citations

This map shows the geographic impact of Peter M.A. Calverley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter M.A. Calverley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter M.A. Calverley more than expected).

Fields of papers citing papers by Peter M.A. Calverley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter M.A. Calverley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter M.A. Calverley. The network helps show where Peter M.A. Calverley may publish in the future.

Co-authorship network of co-authors of Peter M.A. Calverley

This figure shows the co-authorship network connecting the top 25 collaborators of Peter M.A. Calverley. A scholar is included among the top collaborators of Peter M.A. Calverley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter M.A. Calverley. Peter M.A. Calverley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Loading papers...

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M.K. Simon Breakdown of academic impact, for papers by Richard E. Kuntz Breakdown of academic impact, for papers by Harry Hemingway Breakdown of academic impact, for papers by James E. Muller Breakdown of academic impact, for papers by Yasuhiro Matsumura Breakdown of academic impact, for papers by Shaoyi Jiang Breakdown of academic impact, for papers by Jianyong Ouyang Breakdown of academic impact, for papers by Carl Wieman
Rankless by CCL
2026